<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00151320</url>
  </required_header>
  <id_info>
    <org_study_id>0309006313</org_study_id>
    <nct_id>NCT00151320</nct_id>
  </id_info>
  <brief_title>Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL</brief_title>
  <official_title>Phase I/II Trial of VELCADE+ CHOP-Rituximab in Patients With Previously Untreated Diffuse Large B Cell or Mantle Cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To determine the toxicity profile and maximum tolerated dose (MTD) of VELCADE when
      administered in combination with CHOP + Rituximab to patients with previously untreated
      diffuse large B cell or mantle cell non-Hodgkin's lymphoma (NHL)

      Secondary Objectives:

      To assess the response rate (overall and complete), event-free survival and overall survival
      with VELCADE and CHOP-R in patients with previously untreated diffuse large B cell or mantle
      cell lymphoma (phase II component)

      Treatment:

      Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles

      Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)

      VELCADE is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of
      VELCADE will be determined by the following dose escalation schedule:

      Level Dose/Schedule (-2) 0.7 mg/m2 on day 1 of each cycle (-1) 0.7 mg/m2 on days 1 and 8 (0)
      0.7 mg/m2 on days 1 and 4 (+1) 1.0 mg/m2 on days 1 and 4 (+2) 1.3 mg/m2 on days 1 and 4
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles

      Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)

      VELCADE is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of
      VELCADE will be determined by the following dose escalation schedule:

      Once completed six cycles of therapy (~18 weeks), patients will be evaluated every 3 months
      for the first year post treatment, then every 6 months until disease progression or death for
      years 2 through 5 post treatment. Patients who have disease progression will be contacted
      every 6 months until death to assess for survival status.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2004</start_date>
  <completion_date type="Actual">April 24, 2013</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles
Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)
VELCADE is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the dose escalation schedule.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>6 cycles (18 weeks)</time_frame>
    <description>Overall Response Rate</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles
Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)
VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by a dose escalation schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib, CHOP, Rituximab</intervention_name>
    <description>Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)
VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the following dose escalation schedule:
Level Dose/Schedule (-2) 0.7 mg/m2 on day 1 of each cycle (-1) 0.7 mg/m2 on days 1 and 8 (0) 0.7 mg/m2 on days 1 and 4 (+1) 1.0 mg/m2 on days 1 and 4 (+2) 1.3 mg/m2 on days 1 and 4</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>VELCADE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of diffuse large B cell or mantle cell
             Non-Hodgkin's Lymphoma with characteristic immunophenotypic profiles. For mantle cell:
             CD5(+), CD19(+) or CD20(+), cyclin D1(+), CD23(-) and CD10(-).

          -  Patient has not received any prior anti-cancer therapy for lymphoma

          -  Tumor tissue confirmed to express the CD20 antigen

          -  Available frozen tumor tissue(rebiopsy if needed)

          -  Patient has measurable disease as defined by a tumor mass &gt; 1.5 cm

          -  Patient has Stage II, III, or IV disease

          -  Age &gt; 18 years

          -  Absolute granulocyte count &gt; 1000 cells/mm3

          -  Platelet count &gt; 50,000 cells/mm3

          -  Creatinine &lt; 2.0 x ULN

          -  Total bilirubin &lt; 2.0 x ULN

        Exclusion Criteria:

          -  Known central nervous system (CNS) involvement by lymphoma

          -  Known HIV disease

          -  Patient is pregnant or nursing

          -  Patient has had major surgery within the last 3 weeks

          -  Patient is receiving other investigational drugs

          -  Known peripheral neuropathy &gt; Grade 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Leonard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University College of Physicians and Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <results_first_submitted>February 23, 2017</results_first_submitted>
  <results_first_submitted_qc>February 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 7, 2017</results_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diffuse large B cell</keyword>
  <keyword>mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1</title>
          <description>Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles
Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)
VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by a dose escalation schedule.
Bortezomib, CHOP, Rituximab: Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)
VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the following dose escalation schedule:
Level Dose/Schedule (-2) 0.7 mg/m2 on day 1 of each cycle (-1) 0.7 mg/m2 on days 1 and 8 (0) 0.7 mg/m2 on days 1 and 4 (+1) 1.0 mg/m2 on days 1 and 4 (+2) 1.3 mg/m2 on days 1 and 4</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Untreated DLBCL</title>
          <description>with untreated Diffuse Large B-cell Lymphoma (n = 40)</description>
        </group>
        <group group_id="B2">
          <title>Untreated MCL</title>
          <description>with untreated mantle cell Non-Hodgkin’s Lymphoma</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="20" upper_limit="87"/>
                    <measurement group_id="B2" value="66" lower_limit="45" upper_limit="80"/>
                    <measurement group_id="B3" value="63" lower_limit="20" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ORR</title>
        <description>Overall Response Rate</description>
        <time_frame>6 cycles (18 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Untreated DLBCL</title>
            <description>with untreated Diffuse Large B-cell Lymphoma (n = 40)</description>
          </group>
          <group group_id="O2">
            <title>Untreated MCL</title>
            <description>with untreated mantle cell Non-Hodgkin’s Lymphoma</description>
          </group>
        </group_list>
        <measure>
          <title>ORR</title>
          <description>Overall Response Rate</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles
Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)
VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by a dose escalation schedule.
Bortezomib, CHOP, Rituximab: Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)
VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the following dose escalation schedule:
Level Dose/Schedule (-2) 0.7 mg/m2 on day 1 of each cycle (-1) 0.7 mg/m2 on days 1 and 8 (0) 0.7 mg/m2 on days 1 and 4 (+1) 1.0 mg/m2 on days 1 and 4 (+2) 1.3 mg/m2 on days 1 and 4</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Uroepithelial carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Neutropenia</description>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Anemia</description>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Thrombocytopenia</description>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <description>Deep Vein Thrombosis</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <description>Cardiac Arrhythmia</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <description>Congestive heart failure</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Anorexia</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Constipation</description>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Diarrhea</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <description>Edema</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Vomiting</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <description>Febrile Neutropenia</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Infection (normal ANC)</sub_title>
                <description>Infection (normal ANC)</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Sepsis</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <description>Neuropathy</description>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute renal failure</sub_title>
                <description>acute renal failure</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Dyspnea</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <description>Pleural effusion</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Interstitial pneumonitis</sub_title>
                <description>Interstitial pneumonitis</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Leonard, MD</name_or_title>
      <organization>Weill Cornell Medicine</organization>
      <phone>646.962.2064</phone>
      <email>amr2017@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

